Supply Agreement Opens Access to Oncology Medicines
Jan 10 2020 Read 270 Times
Following a recent agreement signing, global pharmaceutical company and service partner Inceptua Group now offer Bendalis GmbH’s range of generic oncology drugs and specialist therapeutic agents, enabling clinical trial sponsors quick access to Brexit-safe oncology standard of care medicines produced within the European Union.
“With this agreement Bendalis and Inceptua join forces to ensure optimal sourcing and supply of medicines for use in oncology clinical trials to our clients. Together, we share a mission to provide uninterrupted access for patients to high quality products through a secure and robust supply chain,” said Alan Raffensperger, CEO, Inceptua Group.
As a part of the agreement, Bendalis will maintain stock of specific products on a consignment basis, providing contingency against manufacturing issues, stock-out situations and mitigation of study delays which would impact both patients and sponsors.
“In the oncology space we experience a growing need and demand for products. We see Inceptua as the ideal partner to handle the distribution and help optimise the clinical trial supply for clients. A consistent and secure supply of products is a critical component in clinical trials and together we can offer a flexible yet reliable solution, helping clients minimise overage and reduce costs,” says Christian Parvany, CEO, Bendaliss.
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Mass Spectrometry & Spectroscopy - Translating Proteomic MALDi Tissue Typing to Clinical Pathology - Fusion Protein Complexes Analysed by CG-MALS - Non-equivalent, Multivalen...
View all digital editions
Jan 25 2020 San Diego, CA, USA
Jan 27 2020 Dubai, UAE
Jan 29 2020 Tokyo, Japan
Feb 03 2020 Dubai, UAE
Feb 12 2020 Tokyo, Japan